参苓白术散在腹泻型肠易激惹综合征治疗中的价值研究

A study on treating diarrhea-predominant irritable bowel syndrome with Shenling Baizhu San

目的:观察在腹泻型肠易激惹综合征治疗中采取参苓白术散的成效。方法:本次的72例研究对象选自本院2016年1月-2017年12月期间接收的腹泻型肠易激惹综合征患者,将其按照不同治疗方式分为对照组和观察组。对照组采用培菲康进行治疗,观察组采用培菲康联合参苓白术散进行治疗,观察两组患者的临床治疗成效。结果:观察组的治疗总成效为94.44%,相比对照组的77.78%,组间差异明显,有统计学意义(χ2=6.852,P <0.05),另外,治疗后,两组患者的症状积分都得到显著改善,且观察组(1.44±0.45)明显优于对照组(4.85±1.08),差异明显,有统计学意义(t=4.228,P <0.05)。结论:对腹泻型肠易激惹综合征患者采取培菲康联合参苓白术散治疗方式,可有效改善患者的临床症状,治疗成效十分明显,加快患者的康复速度,充分体现其价值意义,值得进一步推广采纳。

Objective： To observe the efect of Shenling Baizhu San （参苓白术散） on diarrhea-predominant irritable bowel syndrome. Methods： 72 patients with diarrhea-predominant irritable bowel syndrome were divided into the control group and observation group according to diferent treatment methods. The control group was treated with Bifco. The observation group was treated with Shenling Baizhu San more. Results： The total efciency was 94.44% in the observation group and 77.78% in the control group, with a signifcant diference （χ2=6.852, P〈0.05）. The symptom scores in groups were signifcantly improved; that in the observation group was （1.44±0.45）, and signifcantly better than （4.85±1.08） in the control group （t=4.228, P〈0.05）. Conclusion： Bifco plus Shenling Baizhu San on diarrhea-predominant irritable bowel syndrome shows a very obvious efect, can efectively improve the clinical symptoms, speed up the recovery of patients, fully refects its value and signifcance, is worthy of further promotion and adoption.